Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for intravenous histamine therapy, effective May 15, 2026. Here's what billing teams need to do before that date.
CMS intravenous histamine therapy coverage policy updates don't happen in a vacuum. When CMS moves on a treatment category like this — one that sits at the intersection of allergy management, pain medicine, and investigational therapy — the downstream effect on claim denial rates and reimbursement can be significant. The policy does not carry a numbered policy code in the traditional NCD or LCD format, but it is tracked in the CMS policy system and carries real teeth for any practice or facility billing for this service.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Intravenous Histamine Therapy |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Allergy & Immunology, Pain Management, Internal Medicine, Integrative Medicine |
| Key Action | Audit all pending and active claims for IV histamine therapy before May 15, 2026, and confirm medical necessity documentation meets CMS's updated standard |
CMS Intravenous Histamine Therapy Coverage Criteria and Medical Necessity Requirements 2026
This is where things get complicated — and where your billing team needs to pay close attention.
Intravenous histamine therapy has long occupied uncertain ground in the CMS coverage framework. The treatment involves administering histamine via IV infusion, most often in the context of pain management protocols or desensitization approaches. CMS has historically scrutinized this therapy because the clinical evidence base is narrow and the indications are not standardized across the medical community.
The policy document itself does not list specific CPT or HCPCS codes in the available data. That means your billing team cannot rely on a clean code list to determine exposure. You need to look at what your practice is currently billing for IV histamine administration — typically an infusion code — and evaluate whether that claim will survive scrutiny under the updated coverage policy.
Medical necessity is the central question here. CMS applies a straightforward standard: a service is medically necessary if it is reasonable and necessary for the diagnosis or treatment of an illness or injury, and meets accepted standards of medical practice. For a therapy like IV histamine, that standard is hard to meet when peer-reviewed clinical evidence is thin. If your documentation doesn't explicitly tie the treatment to a covered, well-defined diagnosis with supporting clinical rationale, CMS will not cover it.
Prior authorization is not universally required under this policy based on available data, but that doesn't mean you're in the clear. The absence of a prior authorization requirement shifts the burden entirely onto your documentation and coding accuracy. A claim denial after the fact is harder to recover from than a prior auth review before service.
Whether intravenous histamine therapy is covered under Medicare depends entirely on how the treating physician documents medical necessity. A note that says "patient requested IV histamine therapy" will not survive a post-payment audit. A note that articulates the clinical rationale, the failure of conventional treatment, and the specific diagnosis being treated has a fighting chance.
CMS Intravenous Histamine Therapy Exclusions and Non-Covered Indications
CMS has a consistent pattern with therapies that lack strong clinical evidence: when the evidence doesn't support routine coverage, the agency classifies the service as experimental, investigational, or not reasonable and necessary. IV histamine therapy falls into this risk zone.
The policy data available does not enumerate specific exclusions by indication. That's actually a warning sign, not a relief. When CMS doesn't carve out specific covered indications, it often means the entire category is under scrutiny. Your compliance officer needs to be involved in any decision to continue billing for this service after May 15, 2026.
Treatments administered for general wellness, anti-aging, or non-specific immune modulation will not meet the medical necessity standard. Those claims will be denied. If your practice has been billing IV histamine therapy under broad or vague diagnostic codes, stop that practice immediately.
Coverage Indications at a Glance
Because the policy data does not include specific covered or non-covered indications, this table reflects the general CMS framework applied to therapies in this category. Talk to your compliance officer before billing any indication not supported by peer-reviewed clinical evidence.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| IV histamine therapy with documented medical necessity and conventional treatment failure | Uncertain — requires strong documentation | Not specified in policy data | Must meet CMS "reasonable and necessary" standard |
| IV histamine therapy for general wellness or immune support | Not Covered | Not specified in policy data | Does not meet medical necessity criteria |
| IV histamine therapy classified as experimental or investigational by clinical literature | Not Covered | Not specified in policy data | CMS follows clinical evidence standards; thin evidence = no coverage |
| IV histamine therapy billed under infusion administration codes without specific diagnosis support | High denial risk | Not specified in policy data | Audit these claims before May 15, 2026 |
CMS Intravenous Histamine Therapy Billing Guidelines and Action Items 2026
The modified coverage policy takes effect May 15, 2026. You have a defined window to act. Here's what to do.
| # | Action Item |
|---|---|
| 1 | Audit all active and pending claims for IV histamine therapy before May 15, 2026. Pull every claim your team has submitted in the past 12 months that involves histamine administration via IV infusion. Review the diagnosis codes attached to each claim. If the diagnosis doesn't clearly support medical necessity under CMS standards, flag it for your compliance officer now — not after a denial arrives. |
| 2 | Review and update your clinical documentation templates before May 15, 2026. The physician note must do the heavy lifting. It needs to document the diagnosis, the clinical rationale for IV histamine therapy, prior treatment attempts and their outcomes, and why this therapy is the appropriate next step. Vague notes will not survive a coverage review under the modified policy. |
| 3 | Identify which infusion administration codes your team is using for this service. The policy does not list specific CPT or HCPCS codes. That means your billing team needs to determine which codes appear on your claims for IV histamine services. Document those codes internally so you can monitor denial patterns after the effective date. |
| 4 | Check with your Medicare Administrative Contractor for regional guidance. CMS policies are applied nationally, but your MAC may have issued a local coverage determination or coverage article that affects how this policy plays out in your region. Contact your MAC before May 15, 2026 to confirm whether any local coverage determination adds specificity to the national policy. |
| 5 | Brief your medical director and treating physicians on the documentation standard. This is not a billing team problem in isolation. Physicians need to understand that IV histamine therapy billing guidelines require airtight clinical rationale. Schedule a brief before the effective date — even 20 minutes — to walk through what the documentation needs to include. |
| 6 | Don't bill this service for patients where medical necessity is ambiguous. If the clinical case for IV histamine therapy is marginal, the reimbursement risk isn't worth it. A denied claim costs your team time and money to work. A claim that triggers a post-payment audit costs far more. When in doubt, don't bill it. |
If you're uncertain how this policy change applies to your specific patient population or payer mix, loop in your compliance officer or a healthcare billing consultant before May 15, 2026.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Intravenous Histamine Therapy Under CMS Policy
The policy data for this CMS coverage policy does not include specific CPT, HCPCS, or ICD-10 codes. This is not an oversight — it reflects how the policy is structured. CMS did not enumerate a code list in the available policy document.
That creates a real problem for intravenous histamine therapy billing. Without a defined code set, your team must identify which codes you're currently using to bill this service and evaluate each one against the updated coverage criteria.
What Your Team Should Do in the Absence of a Code List
Work backward from your own claims data. Pull all claims in the past 12 months that involve IV infusion administration codes where the clinical notes reference histamine. Those are your exposure points. Review each one against the medical necessity standard before the effective date of May 15, 2026.
Do not attempt to assign codes based on analogy to similar services without explicit guidance from your compliance officer or a qualified billing consultant. Incorrect code assignment on a service that's already under CMS scrutiny is a compounding risk.
If CMS or your MAC publishes a code list associated with this policy modification, update your charge capture immediately. Monitor the CMS website and your MAC's coverage articles for any follow-up guidance issued before or shortly after May 15, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.